An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
- PMID: 40513558
- DOI: 10.1016/j.stem.2025.05.011
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
Abstract
Deciphering interactions between tumor micro- and systemic immune macroenvironments is essential for developing more effective cancer diagnosis and therapeutic strategies. Here, we established a gel-liquid interface (GLI) co-culture model of lung cancer organoids (LCOs) and paired peripheral-blood mononuclear cells (PBMCs), featuring enhanced interactions between immune cells and tumor organoids for optimized simulation of in vivo systemic anti-tumor immunity. By constructing a cohort of lung cancer patients, we demonstrated that the responses of GLI models under αPD1 treatment reflected the immunotherapy outcomes of the corresponding patients precisely. Furthermore, we dissected the various tumor immune processes mediated by PBMC-derived T cells within GLI models through functional multi-omics analyses, along with the characterization of circulating tumor-reactive T cells (GNLY+CD44+CD9+) with effector memory-like phenotypes as a potential indicator of immunotherapy efficacy. Our findings indicate that the GLI co-culture model can be used to develop diagnostic strategies for precision immunotherapies, as well as understanding the underlying mechanisms.
Keywords: co-culture; gel-liquid interface; immune checkpoint inhibitors; lung cancer; peripheral blood mononuclear cells; precision immunotherapy; single-cell RNA sequencing; systemic immune response; tumor organoids; tumor-reactive T cells.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests P.L., K.L., and C. Liu are the co-inventors of a patent on GLI organoid co-culture technology assigned to Tsinghua University (A method for co-culturing multicellular spheroids with cells, CN 117264896 A).
Similar articles
-
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025. Front Immunol. 2025. PMID: 40777041 Free PMC article.
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.J Immunother Cancer. 2023 Apr;11(4):e006267. doi: 10.1136/jitc-2022-006267. J Immunother Cancer. 2023. PMID: 37072346 Free PMC article.
-
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs).J Vis Exp. 2025 Jun 27;(220). doi: 10.3791/68346. J Vis Exp. 2025. PMID: 40658622
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2021 Dec 6;12:CD011300. doi: 10.1002/14651858.CD011300.pub3. PMID: 29247502 Free PMC article. Updated.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous